LIBX-A401

Overview

LIBX-A401 is a selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor with a human IC 50 values of 0.38 μM and a K d of 0.72 μM. LIBX-A401 binds to ACSL4 in an ATP-dependent manner, stabilizes the C-terminal domain, alters the fatty acid gate region, and interacts with residues A329 and Q302 within the fatty acid binding site. LIBX-A401 exhibits anti- ferroptosis properties in cells. LIBX-A401 can be used for the researches of cancer and parkinson's disease.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Parkinson's Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ACSL Family | Products > Signaling Pathways > Ferroptosis

Product Information

• Catalog No.: HY-173432
• CAS No.: 3111845-07-6
• Molecular Formula: C20H21NO4
• Molecular Weight: 339.39
• Purity: 99.9%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution
• Availability: In-stock

Source

Original product source